Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Blinatumomab Bridging Therapy in High-Risk B-Acute Lymphoblastic Leukemia: A Phase 2 Study

NCT04556084 is registered in ClinicalTrials.gov with Michael Burke as lead sponsor.

NCT NCT04556084
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04556084 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Blinatumomab Bridging Therapy in High-Risk B-Acute Lymphoblastic Leukemia: A Phase 2 Study
Lead sponsor
Michael Burke
Phase
Phase 2
Overall status
Terminated
Start date
January 1, 2021
Completion date
October 1, 2022
Enrollment
2 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell acute lymphoblastic leukemia, refractory b acute lymphoblastic leukemia, relapsed b-cell acute lymphoblastic leukemia